01—Abstract
Summary
Summary of the 8-K filed April 2, 2026. Cited figures are marked; the original filing is the authoritative source.
Illumina, Inc. (NASDAQ: ILMN) disclosed in an 8-K filed April 2, 2026 that three directors, Drs.
Frances Arnold, Robert S. Epstein and Gary S. Guthart, notified the Board of their intention to retire as directors, effective May 21, 2026, the date of the Company's 2026 annual meeting of stockholders.
The filing states that the retirements are not the result of any dispute or disagreement with the Company or the Board on any matter relating to its operations, policies or practices. In a related press release furnished as Exhibit 99.1, the Company announced that the Board has nominated David P. King for election as a director at the 2026 annual meeting.
The release describes Mr. King as the former Executive Chairman and CEO of Laboratory Corporation of America Holdings, a current director and chair of Privia Health and AmSurg Corporation, and a director of Smith & Nephew, with prior board positions at ZimVie and VaxCare. Board Chair Scott Gottlieb, MD, credited the departing directors with helping steer the company through a period of transformation. The filing is a governance update.
It contains no financial results, guidance or quantitative metrics. The Item 7.01 disclosure, including Exhibit 99.1, is furnished rather than filed for purposes of Section 18 of the Exchange Act.
02—Key points
Key Highlights
- Drs. Frances Arnold, Robert S. Epstein and Gary S. Guthart notified the Board on April 2, 2026 of their intention to retire as directors, effective May 21, 2026.
- The filing states the retirements are not the result of any dispute or disagreement with the Company or the Board on operations, policies or practices.
- The Board has nominated David P. King for election as a director at the 2026 annual meeting of stockholders.
- Mr. King is described as the former Executive Chairman and CEO of Laboratory Corporation of America Holdings and a current director of Privia Health, AmSurg Corporation and Smith & Nephew.
- Board Chair Scott Gottlieb, MD, praised the retiring directors' sound judgment and steady commitment during a period of transformation for the company.
- The 2026 annual meeting of stockholders is scheduled for May 21, 2026, per the filing.
- The filing contains no financial results, guidance or quantitative metrics.
03—Questions
Frequently Asked Questions
Why are Frances Arnold, Robert S. Epstein and Gary S. Guthart leaving the Board?
The filing states they notified the Board of their intention to retire, and that the retirements are not the result of any dispute or disagreement with the Company or the Board on any matter relating to its operations, policies or practices. The filing does not give further reasons.
When will the board changes take effect?
The retirements of Drs. Arnold, Epstein and Guthart are effective as of May 21, 2026, the date of the Company's 2026 annual meeting of stockholders.
Who is David P. King and what is his role?
The Board has nominated David P. King for election as a director at the 2026 annual meeting. The press release describes him as the former Executive Chairman and CEO of Laboratory Corporation of America Holdings, with current board roles at Privia Health, AmSurg Corporation and Smith & Nephew, and prior board positions at ZimVie and VaxCare.
Does this filing include any financial results or guidance?
No. The filing covers changes in board membership under Item 5.02 and a related press release under Item 7.01. It does not include financial results, guidance or other quantitative financial information.
04—Continue